Across TCGA pan-cancer cohorts, ARRDC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARRDC1 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARRDC1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARRDC1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ARRDC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.929	0.749	.006	22	view →
LUAD	OS	Median	All	1.000	0.926	.004	11	view →
PDAC	OS	Median	III,IV	0.558	0.889	.019	8	view →
LSCC	DFS	Median	All	0.896	0.976	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ARRDC1 tumor-vs-normal RNA expression · all ARRDC1 data types